Varian's FlashForward Consortium adds new member
The South Florida Proton Therapy Institute of Delray Beach has joined radiation...Read more on AuntMinnie.comRelated Reading: Varian CEO rings NYSE opening bell on World Cancer Day Varian to present mobile app at HIMSS 2019 Varian posts Q1 revenue gains 1st Taiwanese patients treated with Varian HyperArc Varian gets Chinese trade tariff exemption
Penn Medicine Lancaster General Health has started construction of a $48 million proton therapy center. The proton therapy center, part of Lancaster General Health's Ann B. Barshinger Cancer Institute, will be the second site in Pennsylvania to offer the high-tech form of radiation therapy to cancer patients when it opens in the fall of 2021. The first proton therapy center in Pennsylvania opened a t Penn, in a 75,000-square-foot building that is part of the Abramson Cancer Center, in 2010. Penn…
Condition: Pediatric Cancer Intervention: Sponsor: St. Jude Children's Research Hospital Not yet recruiting
The Proton Therapy Center operated by Cincinnati Children ’s Hospital and UC Health has hit a significant milestone in researching the use of high doses of proton beams delivered at ultra-high speeds to treat cancer. The advancement in so-called flash therapy, which is delivered in one to three sessions that each last less than one second, is a step tow ard clinical trials. Equipment maker Varian Medical Systems of Palo Alto, Calif., has been researching the value of such ultra-high-dose-rate proton…
ConclusionsInstitution of a BP biologic dose constraint may reduce brachial plexopathy risk without compromising target coverage. MCBD plan evaluation provides valuable information to physicians that may assist in making clinical judgments regarding relative priority of target coverage versus normal tissue sparing.
In conclusion, this numerical study suggests that the ionoacoustic wave field may well be used to monitor the proton dose distribution during breast cancer treatment. PMID: 31600743 [PubMed - as supplied by publisher]
Proton therapy is a form of external beam radiotherapy that has several advantages over conventional photon (x-ray) radiotherapy. Protons are useful in 2 scenarios that apply to a large proportion of cancer patients: lack of exit dose allows for delivery of a therapeutic radiation dose to tumors in challenging anatomic locations, and reduction in integral dose (low-dose bath) to normal tissues that may reduce the risk of late toxicities and secondary cancers. The emergence of smaller, more economically viable single-room proton units has led to the expansion in use of this technology across the world.
CONCLUSIONS: MCT optimization can improve plan robustness toward anatomical change and may reduce the number of plan adaptation for head and neck cancers. PMID: 31564553 [PubMed - as supplied by publisher]
We aimed to determine whether multiple-CT (MCT) optimization of intensity-modulated proton therapy (IMPT) could improve plan robustness to anatomical changes and therefore reduce the additional need for adaptive planning.
Abstract Background: The aim of this study was to compare adaptive intensity modulated proton therapy (IMPT) robustness and organ sparing capabilities with that of adaptive volumetric arc photon therapy (VMAT). Material and methods: Eighteen lung cancer patients underwent a planning 4DCT (p4DCT) and 5 weekly repeated 4DCT (r4DCT) scans. Target volumes and organs at risk were manually delineated on the three-dimensional (3D) average scans of the p4DCT (av_p4DCT) and of the r4DCT scans (av_r4DCT). Planning target volume (PTV)-based VMAT plans and internal clinical target volume (ICTV)-based robust IMPT plans were op...
High-dose fractionated proton therapy is used to manage patients with skull base tumors such as clival chordomas or chondrosarcomas [8,14]. Proton therapy is also used in the treatment of patients with lower grade gliomas , meningiomas, and subsets of head and neck cancer patients with particular dosimetric benefit, such as those with tumors of the paranasal sinuses . Clinical outcomes support the utility of proton therapy in the disease control of these tumors but little is known on potential late side effects of brain radiation necrosis.